Magellan Diagnostics LeadCare II Blood Lead Test Kit Class II Recall
Summary
FDA classified a Class II recall for Magellan Diagnostics LeadCare II Blood Lead Test Kit on April 17, 2026 (Recall No. Z-1893-2026). The firm initiated the field correction on March 13, 2026 after discovering that use of certain third-party micro-collection devices produced false positive blood lead results, which may cause delayed diagnosis and unnecessary additional testing. Approximately 197,893 units were distributed worldwide. The recall does not require product removal from the field.
“The only blood collection devices validated for use with the Magellan LeadCare II Blood Lead Test Kit are the capillary tubes provided in the LeadCare II Test Kit.”
What changed
FDA classified a Class II recall for Magellan Diagnostics LeadCare II Blood Lead Test Kit after determining that device design caused false positive results when certain third-party micro-collection devices were used to collect capillary samples. The firm determined the root cause was device design and issued medical device field correction letters to customers on March 13, 2026.
Healthcare providers and laboratories using LeadCare II, LeadCare Plus, or LeadCare Ultra systems must review their blood collection procedures. LeadCare II users should exclusively use the capillary tubes included in the kit. LeadCare Plus and Ultra users must validate alternative micro-collection devices under their laboratory policies. Any patient who received elevated results using these systems should be scheduled for confirmatory testing per CDC guidelines. The product remains available as no field removal was required.
What to do next
- Use only the capillary tubes provided in the LeadCare II Test Kit for blood sample collection — no other collection device is validated for use with the LeadCare II System.
- Validate micro-collection devices with LeadCare Plus and Ultra Blood Lead Testing Systems in accordance with laboratory policies and procedures.
- Patients with elevated results on LeadCare Blood Lead Test Systems should have confirmatory testing performed in accordance with CDC or other applicable standards and guidelines.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Class 2 Device Recall Magellan Diagnostics LeadCare II Blood Lead Test Kit
- Databases
| 510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards |
| CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | |
| New Search | ) |
| | Class 2 Device Recall Magellan Diagnostics LeadCare II Blood Lead Test Kit | |
| Date Initiated by Firm | March 13, 2026 |
|---|---|
| Date Posted | April 17, 2026 |
| Recall Status | Open , Classified |
| Recall Number | Z-1893-2026 |
| Recall Event ID | 98502 |
| 510(K)Number | K052549 |
| Product Classification | Lead, atomic absorption - Product Code DOF |
| Product | (1)(2) LeadCare II Blood Lead Test Kit, (3)LeadCare II 5X Blood Lead Test Kit, (4)LeadCare II 9X Blood Lead Test Kit ; |
Catalog Number(s): (1) 70-6762, (2) 70-6762RUO, (3) 70-8404 (Box containing 5 Test Kits), (4) 70-9000 (Box containing 9 test kits);
The LeadCare II kit is provided with the following materials:
" Sensors (2 Containers of 24 sensors each; 48 tests)
" Treatment Reagent Tubes (2 packages of 24 tubes each; 48 tests)
" Heparinized Capillary Tubes/Plungers (50 @)
" Transfer Droppers (50 @)
" Calibration Button (1 @)
" Lead Control Level 1 (1 @ 2 mL)
" Lead Control Level 2 (1 @ 2 mL) |
| Code Information | Catalog Number(s): (1) 70-6762, (2) 70-6762RUO;
UDI-DI: 00850355006000;
ALL lots and ALL sublots;
Catalog Number(s): (3) 70-8404;
UDI-DI: 00850355006086;
ALL lots and ALL sublots;
Catalog Number(s): (4) 70-9000;
UDI-DI: 00850355006093;
ALL lots and ALL sublots; |
| FEI Number | 1218996 |
| Recalling Firm/
Manufacturer | Magellan Diagnostics, Inc.
101 Billerica Ave Bldg 4
North Billerica MA 01862-1271 |
| For Additional Information Contact | Magellan Diagnostics, Inc. Technical Services
800-272-0102 |
| Manufacturer Reason
for Recall | Customers reported observing unexpectedly elevated results when using certain third-party micro-collection devices to collect capillary samples for testing with the LeadCare Test Systems. False positive lead results may cause delayed results and additional unnecessary testing. |
| FDA Determined
Cause | Device Design |
| Action | On March 13, 2026, MEDICAL DEVICE FIELD CORRECTION letters were sent to customers.
REQUIRED ACTIONS:
This field action does NOT require removal of product from the field. The LeadCare Test Systems continue to perform as intended when used according to the product labeling and Instructions for Use.
The regulatory status of all products noted above remains unchanged and the product supply uninterrupted. Technical and customer support will continue as normal.
LEADCARE II: The only blood collection devices validated for use with the Magellan LeadCare II Blood Lead Test Kit are the capillary tubes provided in the LeadCare II Test Kit. No other collection device should be used for blood sample collection for testing with the LeadCare II System.
LEADCARE PLUS AND ULTRA: End users must validate the use of micro-collection devices with LeadCare Plus and LeadCare Ultra Blood Lead Testing Systems in accordance with their laboratory policies and procedures.
REGARDING PREVIOUS RESULTS: Patients who have had elevated results when tested on the LeadCare Blood Lead Test Systems (LeadCare II, LeadCare Plus, and LeadCare Ultra) should have confirmatory testing performed in accordance with CDC or other applicable standards and guidelines. |
| Quantity in Commerce | 197893 |
| Distribution | Worldwide - US Nationwide and the countries of Argentina, Australia, Bhutan, Bolivia, Canada, Chile, Diego Garcia, Ecuador, Eritrea, Georgia, Ghana, Guam, Guatemala, Haiti, Hong Kong, India, Indonesia, Israel, Italy, Ivory Coast, Japan, Kyrgyzstan, Mexico, Nepal, Peru, Philippines, South Africa, South Korea, Spain, UAE, Uruguay, Vietnam. |
| Total Product Life Cycle | TPLC Device Report |
| 1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes. | |
| 510(K) Database | 510(K)s with Product Code = DOF |
Named provisions
Related changes
Get daily alerts for FDA Device Recalls (Class II)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when FDA Device Recalls (Class II) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.